This case report describes a rare case of a persistent canine papillomavirus type 1 (CPV-1)-induced oral papilloma that underwent malignant transformation into an oral squamous cell carcinoma (OSCC) in a 3-year-old Labrador retriever cross. Initially, the patient had multiple and multifocal verrucous lesions populating the oral cavity exclusively. The papillomas persisted despite multiple surgical ablations, azithromycin, interferon α-2b, alternative medicines, and off-label drug use of an immunostimulant. After 1 year and 6 months, an aggressive lesion developed at the level of the left mandibular first molar (309) and progressed to a well-differentiated invasive OSCC. The presence of CPV-1 DNA in the OSCC, and the known oncogenic abilities of CPV-1, suggests that this virus might have played a significant role in the emergence of the OSCC that ultimately led to the patient’s euthanasia due to poor quality of life. This is the first well-documented case where OSCC has developed from an oral papilloma caused by CPV-1 in which the presence of coinfection by another papillomavirus was excluded by multiple polymerase chain reaction tests using various primers.
SuzichJAGhimSJPalmer-HillFJ. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25):11553–11557.
4.
ModisY. Atomic model of the papillomavirus capsid. Embo J. 2002;21(18):4754–4762.
5.
JainSMooreRAAndersonDMGoughGWStanleyMA. Cell-mediated immune responses to COPV early proteins. Virology. 2006;356(1-2):23–34.
DeVilliersEMFauquetCBrokerTRBernardHUzur HausenH. Classification of papillomaviruses. Virology. 2004;324(1):17–27.
8.
LangeCEZollingerSToblerKAckermannMFavrotC. Clinically healthy skin of dogs is a potential reservoir for canine papillomaviruses. J Clin Microbiol. 2010;49(2):707–709.
IsegawaNOhtaMShirasawaHTokitaHYamauraASimizuB. Nucleotide-sequence of a canine oral papillomavirus containing a long noncoding region. Int J Oncol. 1995;7(1):155–159.
YuanHGhimSNewsomeJ. An epidermotropic canine papillomavirus with malignant potential contains an E5 gene and establishes a unique genus. Virology. 2007;359(1):28–36.
13.
LuffJRowlandPMaderMOrrCYuanH. Two canine papillomaviruses associated with metastatic squamous cell carcinoma in two related Basenji dogs. Vet Pathol. 2016;53(6):1160–1163.
14.
ToblerKFavrotCNespecaGAckermannM. Detection of the prototype of a potential novel genus in the family Papillomaviridae in association with canine epidermodysplasia verruciformis. J Gen Virol. 2006;87(12):3551–3557.
15.
LangeCEToblerKAckermannMPanakovaLThodayKLFavrotC. Three novel canine papillomaviruses support taxonomic clade formation. J Gen Virol. 2009;90(11):2615–2621.
16.
LangeCEToblerKLehnerAVetschEFavrotC. A case of a canine pigmented plaque associated with the presence of a Chi-papillomavirus. Vet Dermatol. 2011;23(1):76–80, e18-e19.
17.
YuanHLuffJZhouD. Complete genome sequence of canine papillomavirus type 9. J Virol. 2012;86(10):5966–5966.
18.
LuffJMoorePZhouD. Complete genome sequence of canine papillomavirus type 10. J Virol. 2012;86(20):11407–11407.
19.
ZhouDLuffJUsudaY. Complete genome sequence of canine papillomavirus type 11. Genome Announcs. 2014;2(3):e00529–e00514.
20.
ZhouDLuffJPaulS. Complete genome sequence of canine papillomavirus virus type 12. Genome Announc. 2015;3(2):e00294–e00215.
21.
LangeCEAckermannMFavrotCToblerK. Entire genomic sequence of novel canine papillomavirus type 13. J Virol. 2012;86(18):10226–10227.
22.
LangeCEToblerKSchranerEM. Complete canine papillomavirus life cycle in pigmented lesions. Vet Microbiol. 2013;162(2-4):388–395.
23.
LuffJMaderMBrittonM. Complete genome sequence of canine papillomavirus type 16. Genome Announc. 2015;3(3):e00404–e00415.
24.
MundayJSTuckerRSKiupelMHarveyCJ. Multiple oral carcinomas associated with a novel papillomavirus in a dog. J Vet Diagn Invest. 2015;27(2):221–225.
25.
MundayJSDunowskaMLaurieREHillsS. Genomic characterization of canine papillomavirus type 17, a possible rare cause of canine oral squamous cell carcinoma. Vet Microbiol. 2016;182:135–140.
26.
LangeCEDialloAZeweCFerrerL. Novel canine papillomavirus type 18 found in pigmented plaques. Papillomavirus Res. 2016;2:159–163.
27.
TiszaMJYuanHSchlegelRBuckCB. Genomic sequence of canine papillomavirus 19. Genome Announc. 2016;4(6):e01380–e01316.
28.
LangeCEFavrotC. Canine papillomaviruses. Vet Clin North Am Small Anim Pract. 2011;41(6):1183–1195.
29.
SchweglerKWalterJHRudolphR. Epithelial neoplasms of the skin, the cutaneous mucosa and the transitional epithelium in dogs: an immunolocalization study for papillomavirus antigen. J Vet Med A. 1997;44(1-10):115–123.
30.
ChambersVCEvansCAWeiserRS.Canine oral papillomatosisII. Immunologic aspects of the disease. Cancer Res. 1960;20(7):1083–1093.
GoldschmidtMHKennedyJSKennedyDR. Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted x-linked SCID dogs. J Virol. 2006;80(13):6621–6628.
33.
SundbergJPSmithEKHerronAJJensonABBurkRDVan RanstM. Involvement of canine oral papillomavirus in generalized oral and cutaneous verrucosis in a Chinese Shar Pei dog. Vet Pathol. 1994;31(2):183–187.
34.
LucroyMDHillFIMoorePFMadewellBR. Cutaneous papillomatosis in a dog with malignant lymphoma following long-term chemotherapy. J Vet Diagn Invest. 1998;10(4):369–371.
35.
CallanMBPreziosiDMauldinE. Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. Vet Dermatol. 2005;16(5):338–345.
36.
ChevilleNFOlsonC. Cytology of the canine oral papilloma. Am J Pathol. 1964;45(5):849–872.
37.
NichollsPKMoorePFAndersonDM. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology. 2001;283(1):31–39.
38.
NichollsPKStanleyMA. The immunology of animal papillomaviruses. Vet Immunol Immunopathol. 2000;73(2):101–127.
39.
PorcellatoIBrachelenteCGuelfiG. A retrospective investigation on canine papillomavirus 1 (CPV1) in oral oncogenesis reveals dogs are not a suitable animal model for high-risk HPV-induced oral cancer. PLoS One. 2014;9(11):e112833.
40.
Kuntsi-VaattovaaraHVerstraeteFJMNewsomeJTYuanH. Resolution of persistent oral papillomatosis in a dog after treatment with a recombinant canine oral papillomavirus vaccine. Vet Comp Oncol. 2003;1(1):57–63.
41.
FisherSEFrameJW. The effects of the carbon dioxide surgical laser on oral tissues. Br J Oral Maxillofac Surg. 1984;22(6):414–425.
42.
FrameJW. Removal of oral soft tissue pathology with the CO2 laser. J Oral Maxillofac Surg. 1985;43(11):850–855.
43.
YacBBUralKOcalNHaydardedeoluAE. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial. Vet Dermatol. 2008;19(4):194–198.
44.
FantiniOVidemontEPinD. Successful treatment of florid papillomatosis in a dog using subcutaneous feline recombinant interferon-omega. Revue Méd. Vét. 2015;166(1-2):25–29.
45.
MegidJDias JuniorJGAguiarDMNardi JúniorGSilvaWBRibeiroMG. Tratamento da papilomatose canina com propionibacterium acnes. Arq Bras Med Vet Zoo. 2001;53(5):574–576.
46.
WatrachAMSmallECaseMT. Canine papilloma: progression of oral papilloma to carcinoma. J Natl Cancer Inst. 1970;45(5):915–920.
47.
SmithEMHoffmanHTSummersgillKSKirchnerHLTurekLPHaugenTH. Human papillomavirus and risk of oral cancer. Laryngoscope. 1998;108(7):1098–1103.
48.
GillisonML. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–720.
49.
TermineNPanzarellaVFalaschiniS. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007). Ann Oncol. 2008;19(10):1681–1690.
50.
McKaigRGBaricRSOlshanAF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck. 1998;20(3):250–265.
51.
MundayJSFrenchAHarveyCJ. Molecular and immunohistochemical studies do not support a role for papillomaviruses in canine oral squamous cell carcinoma development. Vet J. 2015;204(2):223–225.
52.
FalkSBannisterKDickensonAH. Cancer pain physiology. Br J Pain. 2014;8(4):154–162.
53.
RaphaelJAhmedzaiSHesterJ. Cancer pain: part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010;11(5):742–764.
54.
ModiMRastogiSKumarA. Buprenorphine with bupivacaine for intraoral nerve blocks to provide postoperative analgesia in outpatients after minor oral surgery. J Oral Maxillofac Surg. 2009;67(12):2571–2576.
55.
SnyderLBCSnyderCJHetzelS. Effects of buprenorphine added to bupivacaine infraorbital nerve blocks on isoflurane minimum alveolar concentration using a model for acute dental/oral surgical pain in dogs. J Vet Dent. 2016;33(2):90–96.
56.
KirkseyMAHaskinsSCChengJLiuSS. Local anesthetic peripheral nerve block adjuvants for prolongation of analgesia: a systematic qualitative review. PLoS One. 2015;10(9):e0137312.
57.
HaasD. An update on analgesics for the management of acute postoperative dental pain. J Can Dent Assoc. 2002;68(8):476–482. PMID: 12323103.
58.
GaynorJS. Control of cancer pain in veterinary patients. Vet Clin North Am Small Anim Pract. 2008;38(6):1429–1448.
59.
KuKanichB. Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. J Vet Pharmacol Ther. 2010;33(1):15–21.
60.
RoseMAKamPC. Gabapentin: pharmacology and its use in pain management. Anesthesia. 2002;57(5):451–462.
61.
VollmerKOvon HodenbergAKölleEU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36(5):830–839.
62.
zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
63.
CampoMS. Papillomavirus and disease in humans and animals. Vet Comp Oncol. 2003;1(1):3–14.
64.
BianchiMVCasagrandeRAWatanabeTTN. Canine papillomatosis: a retrospective study of 24 cases (2001-2011) and immunohistochemical characterization. Pesqui Vet Bras. 2012;32(7):653–657.
65.
SmithKTCampoM. “Hit and run” transformation of mouse c127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology. 1988;164(1):39–47.
66.
ZauggNNespecaGHauserBAckermannMFavrotC. Detection of novel papillomaviruses in canine mucosal, cutaneous and in situ squamous cell carcinomas. Vet Dermatol. 2005;16(5):290–298.
67.
Yi-LingLBorensteinLSelvakumarRAhmedR. Progression from papilloma to carcinoma is accompanied by changes in antibody response to papillomavirus proteins. J Virol. 1993;67(1):382–389.
68.
TeifkeJ. Detection of canine oral papillomavirus-DNA in canine oral squamous cell carcinomas and p53 overexpressing skin papillomas of the dog using the polymerase chain reaction and non-radioactive in situ hybridization. Vet Microbiol. 1998;60(2-4):119–130.
69.
BredalWPThoresenSIRimstadEAleksandersentMNafstadtPHJ. Diagnosis and clinical course of canine oral papillomavirus infection. J Small Anim Pract. 1996;37(3):138–142.
70.
JunDYiGNaT. Canine oral papillomavirus infection: clinical course, pathology, L1 gene and Ncr2 gene sequencing. Isr J Vet Med. 2010;65(3):111–116.
71.
BregmanCLHirthRSSundbergJPChristensenEF. Cutaneous neoplasms in dogs associated with canine oral papillomavirus vaccine. Vet Pathol. 1987;24(6):477–487.
72.
Gutiérrez CastilloCMonerris GarcíaEDolores DuranMSancho MestreMRamón GrasJ. Papillomas & laryngeal papillomatosis treatment with CO2 lasers surgery. Our experience over 15 years. Acta Otorhinolaryngo (English Edition). 2010;61(6):422–427.
73.
ParmarSPlataniasLC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15(6):431–439.
74.
HallHTeuscherCUriePBodenBRobisonR. Induced regression of bovine papillomas by intralesional immunotherapy. Ther Immunol. 1994;1(6):319–324.
75.
DeMounbreunWGoodpastureE. Infectious oral papillomatosis in dogs. Am J Pathol. 1932;(8):43–55.
76.
JohnstonKBMonteiroJMSchultzLD. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes. Virology. 2005;336(2):208–218.
77.
BellJASundbergJPGhimSNewsomeJJensonBSchlegelR. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology. 1994;62(4):194–198.
78.
YuanHEstesPAChenY. Immunization with a Pentameric L1 fusion protein protects against papillomavirus infection. J Virol. 2001;75(17):7848–7853.
79.
StanleyMAMooreRANichollsPK. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in Beagle dogs. Vaccine. 2001;19(20-22):2783–2792.
80.
MooreRAGoughGWSantosEBNichollsPKStanleyMA. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol. 2002;83(9):2299–2301.
81.
KanskyAPoljakMSemeKKocjanB. Human papillomavirus DNA in oral squamous cell carcinomas and normal oral mucosa. Acta Virol. 2003;47(1):11–16.
82.
BoySRensburgEJEngelbrechtSDreyerLHeerdenMHeerdenW. HPV detection in primary intra-oral squamous cell carcinomas – commensal, aetiological agent or contamination?J Oral Pathol Med. 2006;35(2):86–90.
83.
CampoMS. Cell transformation by animal papillomaviruses. J Gen Virol. 1992;73(2):217–222.
84.
SmeetsSJHesselinkATSpeelEJ. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121(11):2465–2472.
85.
MundayJSGibsonIFrenchAF. Papillomaviral DNA and increased p16CDKN2A protein are frequently present within feline cutaneous squamous cell carcinomas in ultraviolet-protected skin. Vet Dermatol. 2011;22(4):360–366.
86.
SabattiniSSaviniFGallinaLScagliariniABassiPBettiniG. P16 immunostaining of canine squamous cell carcinomas is not associated with papillomaviral DNA. PLoS One. 2016;11(7):e0159687.
